2,4-diamino-5-[4-(4-methoxybenzylamino)-3-nitrophenyl]-6-ethylpyrimidine | 118344-94-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-diamino-5-[4-(4-methoxybenzylamino)-3-nitrophenyl]-6-ethylpyrimidine
• 英文别名: 2,4-Diamino-6-ethyl-5-{4-[N-(4-methoxybenzyl)amino]-3-nitrophenyl}pyrimidine；6-Ethyl-5-[4-[(4-methoxyphenyl)methylamino]-3-nitrophenyl]pyrimidine-2,4-diamine
• CAS: 118344-94-8
• 化学式: C₂₀H₂₂N₆O₃
• 分子量: 394.433
• InChiKey: LHLRDEOTXZHYBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  145
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2,4-diamino-5-[4-(4-methoxybenzylamino)-3-nitrophenyl]-6-ethylpyrimidine 在 sodium hydroxide 作用下， 以 乙二醇乙醚 为溶剂， 反应 5.0h， 以98%的产率得到5-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(4-methoxyphenyl)-1H-benzimidazole-3-oxide
  参考文献：
  名称：

  Structural Studies on Bioactive Compounds. 39. Biological Consequences of the Structural Modification of DHFR-Inhibitory 2,4-Diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines (‘benzoprims')

  摘要：

  Benzimidazole-N-oxide modifications of potent lipophilic dihydrofolate reductase (DHFR) inhibitors (e.g., methylbenzoprim 1 and dichlorobenzoprim 2) have been prepared by basepromoted cyclization of the nitrophenylbenzylamino groups to explore the possibility that abrogation of DHFR-inhibitory activity might reveal clues to an alternative anti-ras mechanism. Examples of the new series had only low growth inhibitory activities (Gi(50) generally > 50 muM) against colon HCT116 and lung HT29 cell lines but, unlike methylbenzoprim, this activity was unaffected by hypoxanthine/thymidine rescue.

  DOI：

  10.1021/jm040785+
• 作为产物：
  描述：

  4-甲氧基苄胺 、 2,4-二氨基-5-(3-氨基-4-氯-5-硝基苯基)-6-乙基嘧啶 反应 6.0h， 以35%的产率得到2,4-diamino-5-[4-(4-methoxybenzylamino)-3-nitrophenyl]-6-ethylpyrimidine
  参考文献：
  名称：

  生物活性化合物的结构研究。8.具有抗甲氨蝶呤抗性肿瘤细胞系的体内活性的一系列新的2，4-二氨基-5-芳基-6-乙基嘧啶二氢叶酸还原酶抑制剂的合成，晶体结构和生物学特性。

  摘要：

  合成了一系列在5-芳基环中包含碱性取代基的2,4-二氨基-5-芳基-6-乙基嘧啶，并评估了其对大鼠肝二氢叶酸还原酶（DHFR）的抑制活性。对于在苯环的4位带有苄氨基（19）或N-烷基苄基氨基取代基（29和30）而在3位带有硝基的化合物（相应的3-氨基，3-叠氮基或未取代的类似物，仅被证明是弱活性或无活性的DHFR抑制剂。还筛选了针对甲氨蝶呤耐药性肿瘤，M5076鼠网状肉瘤的体内所选化合物，以及针对DHFR，（3,4-二氯苄基）氨基类似物26的一般平行活性的抗肿瘤活性，该化合物被证明毒性最低，显示出显着的抗肿瘤活性。

  DOI：

  10.1021/jm00131a009

文献信息

• ANTIFOLATE AGENTS
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0290558B1

  公开（公告）日：1993-06-16
• US4992444A
  申请人：——

  公开号：US4992444A

  公开（公告）日：1991-02-12
• Structural studies on bioactive compounds. 8. Synthesis, crystal structure and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line
  作者：Roger J. Griffin、Michelle A. Meek、Carl H. Schwalbe、Malcolm F. G. Stevens

  DOI：10.1021/jm00131a009

  日期：1989.11

  A series of 2,4-diamino-5-aryl-6-ethylpyrimidines embracing basic substituents in the 5-aryl ring was synthesized and evaluated for inhibitory activity against rat liver dihydrofolate reductase (DHFR). Maximal enzyme inhibition was observed for compounds bearing a benzylamino (19) or N-alkylbenzylamino substituent (29 and 30) in the 4-position of the phenyl ring and a nitro group in the 3-position

  合成了一系列在5-芳基环中包含碱性取代基的2,4-二氨基-5-芳基-6-乙基嘧啶，并评估了其对大鼠肝二氢叶酸还原酶（DHFR）的抑制活性。对于在苯环的4位带有苄氨基（19）或N-烷基苄基氨基取代基（29和30）而在3位带有硝基的化合物（相应的3-氨基，3-叠氮基或未取代的类似物，仅被证明是弱活性或无活性的DHFR抑制剂。还筛选了针对甲氨蝶呤耐药性肿瘤，M5076鼠网状肉瘤的体内所选化合物，以及针对DHFR，（3,4-二氯苄基）氨基类似物26的一般平行活性的抗肿瘤活性，该化合物被证明毒性最低，显示出显着的抗肿瘤活性。
• Structural Studies on Bioactive Compounds. 39. Biological Consequences of the Structural Modification of DHFR-Inhibitory 2,4-Diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines (‘benzoprims')
  作者：Marianne L. Richardson、Karen A. Croughton、Charles S. Matthews、Malcolm F. G. Stevens

  DOI：10.1021/jm040785+

  日期：2004.7.1

  Benzimidazole-N-oxide modifications of potent lipophilic dihydrofolate reductase (DHFR) inhibitors (e.g., methylbenzoprim 1 and dichlorobenzoprim 2) have been prepared by basepromoted cyclization of the nitrophenylbenzylamino groups to explore the possibility that abrogation of DHFR-inhibitory activity might reveal clues to an alternative anti-ras mechanism. Examples of the new series had only low growth inhibitory activities (Gi(50) generally > 50 muM) against colon HCT116 and lung HT29 cell lines but, unlike methylbenzoprim, this activity was unaffected by hypoxanthine/thymidine rescue.